76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
76%
of retail accounts lose money when trading CFDs with this provider.
Investments involve risks and are not suitable for all investors. CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage.
76%
of retail investor accounts lose money when trading CFDs with this provider.
You should consider whether you understand how CFDs work, and whether you can afford to take the high risk of losing your money.
English (International)
Repligen Corp
Closed
SectorHealthcare
130.22 -2.74
Overview
Share price change
24h
Min
129.3
Max
135.34
Income | 40M 5.8M |
|---|---|
Sales | 1.6M 169M |
P/E Sector Avg | 466.89 39.564 |
Profit margin | 3.446 |
Employees | 1,778 |
EBITDA | 2.7M 36M |
Recommendations | Buy |
|---|---|
12 Months Forecast | +32.09% upside |
Next Earnings | 29 Jul 2025 |
|---|
Market Cap | -1.1B 7.2B |
|---|---|
Previous open | 132.96 |
Previous close | 130.22 |
News Sentiment
By Acuity
41%
59%
147 / 376 Healthcare
Technical Score
By Trading Central
Confidence
Strong Bearish Evidence
Repligen Corp Chart
Past performance is not a reliable indicator of future results.
Related News
Peer Comparison
Price change
Repligen Corp Forecast
Price Target
By TipRanks
32.09% upside
12 Months Forecast
Average 177 USD 32.09%
High 207 USD
Low 130 USD
Based on 14 Wall Street analysts offering 12 month price targets forRepligen Corp - Dist in the last 3 months.
Sentiment
By Acuity
147 / 376 Healthcare
News Sentiment
Bullish Evidence
Volatility
Below average
News Volume (RCV)
Below average
Financials
Selling and administration expenses
Operating expenses
Pre-tax profit
Sales
Cost of sales
Gross profit on sales
Interest expense on debt
EBITDA
Operating profit
$
About Repligen Corp
Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.
